— Know what they know.
Not Investment Advice

ALGS NASDAQ

Aligos Therapeutics, Inc.
1W: +0.5% 1M: -10.8% 3M: -5.3% YTD: -39.3% 1Y: -46.2% 3Y: -68.8% 5Y: -98.6%
$5.54
+0.04 (+0.73%)
 
Weekly Expected Move ±6.3%
$5 $5 $6 $6 $6
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 37 · $34.3M mcap · 5M float · 2.91% daily turnover · Short 52% of daily vol

Cash Flow Trends

Operating Cash Flow
-$83M -2.2% ▼
Capital Expenditures
$437K -236.2% ▼
5Y CAGR: -26.7%
Free Cash Flow
-$83M -2.6% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$19M +81.1% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$128M-$96M-$88M-$131M-$24M
Depreciation & Amort.$4M$4M$3M$3M$930K
Stock-Based Comp.$13M$0$13M$8M$5M
Change in Working Capital-$5M-$2M-$10M-$5M-$4M
Other Non-Cash Items$86K$15M$2M$44M-$60M
Operating Cash Flow-$116M-$79M-$79M-$81M-$83M
— Investing Activities —
Capital Expenditures-$892K-$943K-$19K-$130K-$437K
Acquisitions (Net)-$4M$0$0$0$0
Investment Purchases-$19M-$104M-$11K-$108M-$165M
Investment Sales$23M$79M$45M$90M$128M
Other Investing$4M$0$0$0$0
Investing Cash Flow$3M-$26M$45M-$18M-$38M
— Financing Activities —
Net Debt Issuance-$79K-$61K-$96K-$83K-$14K
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$172K$0$71M$0$0
Financing Cash Flow$79M$164K$88M$355K$102M
Net Change in Cash-$34M-$106M$54M-$99M-$19M
Cash End of Period$187M$81M$136M$37M$18M
Free Cash Flow-$117M-$80M-$79M-$81M-$83M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms